| Name | Title | Contact Details |
|---|---|---|
Hunter Veal |
VP of Payor Contracting | Profile |
Flokk is a prominent European manufacturer of workplace furniture, known for its commitment to sustainable and ergonomic design. Established in 2017, the company brings together nine heritage brands, each with a rich history, to promote user well-being and environmental responsibility. Flokk emphasizes innovation in seating solutions and has a strong presence across Europe, Asia, and the US. The company specializes in ergonomic office chairs, height-adjustable desks, meeting tables, and workspace accessories. Flokk prioritizes circular design principles, utilizing recycled materials and ensuring that its products are repairable and recyclable. With a focus on reducing carbon emissions through localized production, Flokk aims for climate-positive operations while supporting physical health through its furniture designs. Headquartered in Norway, Flokk operates production facilities in Switzerland, Poland, Norway, and the US, serving a diverse customer base that includes corporate offices, co-working spaces, and public sector organizations.
The PWHL is first-of-its-kind womens hockey league that brings together the best players in the world. Our league is comprised of six teams in North America, including: PWHL Boston, PWHL Minnesota, PWHL Montréal, PWHL New York, PWHL Ottawa, and PWHL Toronto.
Public Risk Innovation, Solutions, and Management, PRISM, is a member-directed risk sharing pool of counties and public entities committed to providing risk coverage programs and risk management services.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.